-

07:45:51 AM

PYXS Stock News

PYXS - Pyxis Oncology Inc

03/31/23 5:00 PM

Nasdaq : PYXS

low float

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted

RHEA-AI

very positive

03/22/23 6:45 AM

Nasdaq : PYXS

earningslow float

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 First subject dosed in Phase 1 trial of PYX-201; clinical sites being activated and patient screening underway in Phase 1 trial of PYX-106 Strong balance sheet with $180.7 million in cash (including restricted cash) and no

RHEA-AI

positive

03/16/23 7:30 AM

Nasdaq : PYXS

clinical triallow float

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target

RHEA-AI

neutral

02/13/23 8:00 AM

Nasdaq : PYXS

conferenceslow float

Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, Pamela

RHEA-AI

neutral

12/23/22 4:45 PM

Nasdaq : PYXS

low float

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, reported on December 23, 2022 that Pyxis Oncology’s Compensation Committee of the Board of

RHEA-AI

very positive

12/01/22 6:45 AM

Nasdaq : PYXS

low float

Pyxis Oncology Announces FDA Clearance of Two IND Applications

FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate Phase 1 clinical trials of PYX-201 and PYX-106 will evaluate the safety and anti-tumor activity in patients with select solid tumors Dual IND clearances

RHEA-AI

neutral

11/01/22 6:30 AM

Nasdaq : PYXS

earningslow float

Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update

Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate (ADC) platform components Gains exclusive rights to Pfizer’s ADC technology platform and toolkit to certain licensed targets ; Initial multi-target sublicense deal executed with stealth ADC company

RHEA-AI

very positive

09/30/22 5:00 PM

Nasdaq : PYXS

low float

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology, Inc. (Nasdaq: PYXS), a diversified oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients, reported on September 30, 2022

RHEA-AI

very positive

08/15/22 7:00 AM

Nasdaq : PYXS

earningslow float

Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update

• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities • Appointed Rachel Humphrey, M.D., a senior biotech executive with extensive experience in drug development, to its Board of Directors • Cash balance of

RHEA-AI

neutral

07/12/22 6:45 AM

Nasdaq : PYXS

low float

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, reported on July 1, 2022 that Pyxis Oncology’s Board of Directors granted restricted stock units with

RHEA-AI

very positive

PYXS Data

IndustryResearch and Development in Biotechnology
Websitepyxisoncology.com
Security namePyxis Oncology Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2834
Employees38

About Pyxis Oncology Inc

Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.